{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-011080","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.523242+00:00","generated_at":"2026-05-16T00:38:34.436051+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corcept Q4 revenue $202.1M, FY2025 $761.4M; guides FY2026 revenue $900M-$1B","bullets":["Q4 2025 revenue $202.1M (vs $181.9M Q4 2024); full-year revenue $761.4M (vs $675.0M in 2024).","Diluted EPS: Q4 $0.20, FY2025 $0.82 (vs Q4 2024 $0.26, FY2024 $1.23). Net income declined due to stock repurchases and operational costs.","Cash and investments $532.4M at Dec 31, 2025; spent $245.9M on stock repurchases in 2025.","FY2026 revenue guidance $900M-$1B; expects continued Cushing's syndrome business growth.","PDUFA date July 11, 2026 for relacorilant NDA in platinum-resistant ovarian cancer; FDA engaged after CRL for Cushing's NDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-011080","json":"https://secwatch.observer/filing/0001628280-26-011080.json","markdown":"https://secwatch.observer/filing/0001628280-26-011080.md","text":"https://secwatch.observer/filing/0001628280-26-011080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/0001628280-26-011080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:38:34.436051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}